~74 spots leftby Dec 2025

DTAS Workflow vs Standard Triage for Stroke Treatment

Recruiting in Palo Alto (17 mi)
+20 other locations
RG
MR
Overseen byMarc Ribo
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Philips Healthcare
Must not be taking: Oral anticoagulants
Disqualifiers: Coma, Seizures, Terminal illness, others
No Placebo Group
Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on oral anticoagulant therapy with an INR greater than 3.0, you may be excluded from participating.

What data supports the effectiveness of the treatment Direct to Angio Suite (DTAS) for stroke?

Research shows that the Direct to Angio Suite (DTAS) approach for stroke treatment can significantly reduce the time to reperfusion, which is crucial for improving patient outcomes. Studies indicate that faster treatment times are associated with better recovery and reduced disability in stroke patients.12345

Is the Direct to Angio Suite (DTAS) approach generally safe for humans?

The Direct to Angio Suite (DTAS) approach has been studied in stroke patients, and while it aims to improve treatment times, some patients showed intracerebral hemorrhage (bleeding in the brain) on imaging. This suggests that while the approach is generally used to improve outcomes, there are potential safety concerns that need to be considered.23467

How is the DTAS Workflow treatment for stroke different from other treatments?

The DTAS Workflow treatment for stroke is unique because it involves taking patients directly to the angio suite for immediate imaging and potential treatment, using Philips' CBCT (Cone Beam Computed Tomography) technology, which can speed up the process compared to standard triage methods that may involve multiple steps and delays.89101112

Research Team

RG

Raul G Nogueira

Principal Investigator

UPMC Stroke Institute, Pittsburgh

MR

Marc Ribo

Principal Investigator

Vall d'Hebron University Hospital, Barcelona

Eligibility Criteria

The WE-TRUST trial is for adults who've had a stroke, can give consent, and have no major disability from past strokes. They must arrive at the hospital within 6 hours of their stroke starting and have a certain severity score on a neurological scale. People with in-hospital strokes, severe conditions or high blood pressure not suitable for thrombolysis, pregnant women, Philips employees and their families are excluded.

Inclusion Criteria

Your initial NIHSS score before joining the study needs to be 10 points or more.
I suspect I'm having a stroke and can get to a stroke center within 6 hours from when my symptoms started.
I was independent in daily activities before my stroke.
See 4 more

Exclusion Criteria

My doctor expects I have less than one year to live due to my illness.
I do not have bleeding disorders or take blood thinners with INR over 3.0.
You have had a severe allergic reaction to contrast dye in the past.
See 18 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo the Direct to Angio Suite (DTAS) workflow for stroke treatment, utilizing Cone-Beam CT (CBCT) for triage and immediate intervention

Peri-procedural time

Follow-up

Participants are monitored for safety and effectiveness after treatment, with primary outcome measures assessed at 90 ± 14 days

90 ± 14 days
1 visit (in-person) or video call

Safety Monitoring

Monitoring for adverse events and device deficiencies from enrollment until hospital discharge

Up to 5 days

Treatment Details

Interventions

  • Conventional CT/MR triage (Procedure)
  • Direct to Angio Suite (DTAS) Philips' CBCT triage (Device)
Trial OverviewThis study compares two ways to decide treatment for stroke patients: one group goes straight to an imaging suite that uses special CBCT technology (DTAS), while the other follows traditional CT/MR scans. The goal is to see which method leads to better outcomes after the stroke.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Direct tot Angiography Suite (DTAS) triage workflowExperimental Treatment1 Intervention
Group II: Conventional CT/MR triage workflowActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Philips Healthcare

Lead Sponsor

Trials
127
Recruited
200,000+
Roy Jakobs profile image

Roy Jakobs

Philips Healthcare

Chief Executive Officer since 2022

Master's in Business Administration from Radboud University Nijmegen and Università degli Studi di Bologna

Dr. Roy Jakobs profile image

Dr. Roy Jakobs

Philips Healthcare

Chief Medical Officer

MD from McGill University

Philips Clinical & Medical Affairs Global

Lead Sponsor

Trials
61
Recruited
17,600+

Roy Jakobs

Philips Clinical & Medical Affairs Global

Chief Executive Officer since 2022

MBA from Erasmus University Rotterdam

Carla Goulart Peron

Philips Clinical & Medical Affairs Global

Chief Medical Officer since 2023

MD from an unspecified institution

Findings from Research

Rapid reperfusion therapy, such as intravenous thrombolytics and endovascular thrombectomy, significantly improves outcomes in acute ischemic stroke, with every minute saved potentially preserving up to 27 million neurons.
The emerging 'direct to angio' approach aims to streamline patient triage and treatment, potentially reducing the time to reperfusion therapy, though its safety, efficacy, and feasibility are still under review.
Direct Transfer to the Neuroangiography Suite for Patients With Stroke.Desai, SM., Psychogios, M., Khatri, P., et al.[2023]
In a randomized controlled trial involving 60 patients, transferring stroke patients directly to the angio-suite for imaging (DTAS) significantly reduced the time from imaging to groin puncture compared to traditional CT scanner suite imaging (CTT), with a median time of 19 minutes versus 26 minutes.
However, while DTAS improved the speed of imaging to groin puncture, it resulted in a longer time from hospital admission to imaging, and ultimately did not lead to a faster overall time to final angiographic reperfusion compared to CTT.
Direct Transfer to Angio-Suite Versus Computed Tomography-Transit in Patients Receiving Mechanical Thrombectomy: A Randomized Trial.Pfaff, JAR., Schönenberger, S., Herweh, C., et al.[2021]
Direct transfer to the angio-suite (DTAS) for patients with suspected large vessel occlusion stroke significantly reduced workflow times, with median door-to-groin times of 16 minutes compared to 70 minutes for controls.
Patients in the DTAS group showed better clinical outcomes, including a lower NIHSS score at 24 hours and a higher rate of favorable outcomes at 90 days, with an odds ratio of 2.5 for achieving a favorable outcome compared to controls.
Direct Transfer to Angio-Suite to Reduce Workflow Times and Increase Favorable Clinical Outcome.Mendez, B., Requena, M., Aires, A., et al.[2019]

References

Direct Transfer to the Neuroangiography Suite for Patients With Stroke. [2023]
Direct Transfer to Angio-Suite Versus Computed Tomography-Transit in Patients Receiving Mechanical Thrombectomy: A Randomized Trial. [2021]
Direct Transfer to Angio-Suite to Reduce Workflow Times and Increase Favorable Clinical Outcome. [2019]
Direct to angiosuite strategy versus standard workflow triage for endovascular therapy: systematic review and meta-analysis. [2023]
Computed tomography angiography and computed tomography perfusion in ischemic stroke: A step-by-step approach to image acquisition and three-dimensional postprocessing. [2019]
Two aces: transient ischemic attack work-up as outpatient assessment of clinical evaluation and safety. [2016]
Evaluation of direct-to-angiography suite (DTAS) and conventional clinical pathways in stroke care: a simulation study. [2023]
Economics of Minimalist Transcatheter Aortic Valve Replacement: Results From the 3M-TAVR Economic Study. [2023]
Practical considerations for optimizing cardiac computed tomography protocols for comprehensive acquisition prior to transcatheter aortic valve replacement. [2017]
Differences in Inpatient Outcomes After Surgical Aortic Valve Replacement at Transcatheter Aortic Valve Replacement (TAVR) and Non-TAVR Centers. [2021]
Implementation of processes of care to support transcatheter aortic valve replacement programs. [2016]
12.United Statespubmed.ncbi.nlm.nih.gov
The Relationship Between Hospital Stroke Center Designation and TVT Reported Stroke: The Michigan TAVR Experience. [2023]